First Nebraska Trust Co Takes Position in Boston Scientific Corporation $BSX

First Nebraska Trust Co bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 115,159 shares of the medical equipment provider’s stock, valued at approximately $4,915,000.

A number of other large investors have also recently made changes to their positions in BSX. Renaissance Group LLC bought a new position in Boston Scientific during the 4th quarter valued at $28,064,000. Perigon Wealth Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $883,000. Y Intercept Hong Kong Ltd lifted its position in shares of Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after buying an additional 670,060 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after acquiring an additional 28,961 shares during the period. Finally, Meiji Yasuda America Inc purchased a new stake in Boston Scientific in the 4th quarter worth about $4,708,000. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 194,522 shares of company stock worth $9,385,210 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Leerink Partners set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research note on Wednesday, June 24th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Trading Up 2.1%

Shares of BSX opened at $50.39 on Friday. The business’s 50-day moving average price is $46.34 and its 200-day moving average price is $57.86. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock has a market cap of $73.03 billion, a PE ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.